The Conatus Pharmaceuticals’ (CNAT) “Buy” Rating Reiterate at the JMP Securities

Posted under Uncategorized on December 10th, 2016 by

The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.03.

Leave a Comment